Lilly Endowment Decreased Its Stake in Eli Lilly And Company (LLY) by $283.55 Million; Keystone Financial Planning Trimmed Clorox (CLX) Holding as Share Price Rose

The Clorox Company (NYSE:CLX) Logo

Keystone Financial Planning Inc decreased its stake in Clorox (CLX) by 88.29% based on its latest 2018Q3 regulatory filing with the SEC. Keystone Financial Planning Inc sold 11,517 shares as the company’s stock rose 7.73% while stock markets declined. The institutional investor held 1,527 shares of the specialty chemicals company at the end of 2018Q3, valued at $230,000, down from 13,044 at the end of the previous reported quarter. Keystone Financial Planning Inc who had been investing in Clorox for a number of months, seems to be less bullish one the $19.71B market cap company. The stock increased 1.57% or $2.39 during the last trading session, reaching $154.37. About 940,772 shares traded. The Clorox Company (NYSE:CLX) has risen 12.45% since January 19, 2018 and is uptrending. It has outperformed by 12.45% the S&P500. Some Historical CLX News: 12/03/2018 – MOODY’S SAYS CLOROX’S ANNOUNCED PURCHASE OF NUTRANEXT IS CREDIT; 08/05/2018 – Prebiotics and Probiotics Team Up in Renew Life’s First Organic Supplement; 15/03/2018 – Cramer also sits down with the CEOs of Intel, HP Inc. and Clorox; 24/05/2018 – Clorox Anticipates Maintaining Debt-to-Ebitda Ratio Within Target Range of 2-2.5 Times; 07/05/2018 – CLOROX CO FILES FOR POTENTIAL DEBT SHELF OFFERING; SIZE NOT DISCLOSED – SEC FILING; 19/04/2018 – Clorox Announces May 8 Webcast of Company Presentation at Goldman Sachs Global Staples Forum; 13/03/2018 – Hidden Valley First To Leverage Allrecipes’ AmazonFresh Integration; 20/03/2018 – VANTERRA CAPITAL,WM PARTNERS SELLS PLATFORM TO CLOROX FOR $700M; 12/03/2018 – Clorox Estimates Nutranext Acquisition Will Dilute FY19 EPS by 8-12 Cents; 02/05/2018 – CLOROX 3Q EPS CONT OPS $1.37

Lilly Endowment Inc decreased its stake in Eli Lilly And Company (LLY) by 2.17% based on its latest 2018Q3 regulatory filing with the SEC. Lilly Endowment Inc sold 2.65M shares as the company’s stock rose 7.21% while stock markets declined. The institutional investor held 119.40 million shares of the major pharmaceuticals company at the end of 2018Q3, valued at $12.81 billion, down from 122.05M at the end of the previous reported quarter. Lilly Endowment Inc who had been investing in Eli Lilly And Company for a number of months, seems to be less bullish one the $114.59B market cap company. The stock decreased 2.16% or $2.57 during the last trading session, reaching $116.59. About 8.89M shares traded or 85.29% up from the average. Eli Lilly and Company (NYSE:LLY) has risen 32.86% since January 19, 2018 and is uptrending. It has outperformed by 32.86% the S&P500. Some Historical LLY News: 24/05/2018 – Osteoporosis Market and Forecast Analysis Report 2018: Prolia will drive growth of the US market, while Forteo losses will halt growth in Japan and the EU – ResearchAndMarkets.com; 24/04/2018 – Eli Lilly 1Q Animal Health Rev $761.3M; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck; 28/05/2018 – NOVARTIS: IMPROVEMENT IN QUALITY OF LIFE DOMAINS WITH ENTRESTO®; 30/04/2018 – Eli Lilly Names Leena Gandhi to Lead Immuno-Oncology Medical Development; 24/04/2018 – ELI LILLY AND CO LLY.N SEES FY 2018 SHR $4.52 TO $4.62; 23/05/2018 – Merck’s Keytruda succeeds late-stage lung cancer study; 13/04/2018 – OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCE…; 27/03/2018 – BRISTOL-MYERS SQUIBB CO – FDA ALSO GRANTED OPDIVO PLUS YERVOY COMBINATION BREAKTHROUGH THERAPY DESIGNATION FOR THIS POTENTIAL INDICATION; 23/05/2018 – Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on January, 30. They expect $1.37 EPS, up 20.18% or $0.23 from last year’s $1.14 per share. LLY’s profit will be $1.35B for 21.28 P/E if the $1.37 EPS becomes a reality. After $1.39 actual EPS reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts -1.44% negative EPS growth.

Investors sentiment increased to 0.98 in Q3 2018. Its up 0.14, from 0.84 in 2018Q2. It improved, as 37 investors sold LLY shares while 399 reduced holdings. 141 funds opened positions while 286 raised stakes. 794.28 million shares or 1.80% less from 808.82 million shares in 2018Q2 were reported. 558,905 were reported by Utd Serv Automobile Association. Destination Wealth holds 6,700 shares or 0.04% of its portfolio. Skba Cap Ltd Limited Liability Company accumulated 4,950 shares or 0.07% of the stock. 2,563 were reported by Tiedemann Advisors Llc. Lynch & In invested in 0.22% or 6,189 shares. Richard Bernstein Advsrs Limited Liability Corp accumulated 40,347 shares. Peapack Gladstone owns 86,031 shares or 0.45% of their US portfolio. Polar Llp accumulated 81,000 shares. Burney owns 120,944 shares for 0.77% of their portfolio. Juncture Wealth Strategies Limited Liability reported 0.27% in Eli Lilly and Company (NYSE:LLY). Vision Cap Management has invested 0.2% in Eli Lilly and Company (NYSE:LLY). Cibc Ww Mkts has invested 0.04% in Eli Lilly and Company (NYSE:LLY). Choate Inv Advsrs holds 0.14% or 23,272 shares in its portfolio. Qs Invsts Ltd, New York-based fund reported 96,566 shares. Jolley Asset Limited Liability invested in 0.16% or 2,210 shares.

More notable recent Eli Lilly and Company (NYSE:LLY) news were published by: Fool.com which released: “Forget GlaxoSmithKline, Eli Lilly Is a Better Big Pharma Stock – The Motley Fool” on December 29, 2018, also Seekingalpha.com with their article: “Eli Lilly to acquire Loxo Oncology for $8B – Seeking Alpha” published on January 07, 2019, Seekingalpha.com published: “Eli Lilly: Loxo To Drive Growth? – Seeking Alpha” on January 08, 2019. More interesting news about Eli Lilly and Company (NYSE:LLY) were released by: Seekingalpha.com and their article: “Eli Lilly: An Update – Seeking Alpha” published on January 17, 2019 as well as Investorplace.com‘s news article titled: “7 Pharmaceutical Stocks That Just Raised Prices This Year – Investorplace.com” with publication date: January 11, 2019.

Among 25 analysts covering Eli Lilly and Company (NYSE:LLY), 12 have Buy rating, 0 Sell and 13 Hold. Therefore 48% are positive. Eli Lilly and Company had 123 analyst reports since July 23, 2015 according to SRatingsIntel. BMO Capital Markets maintained Eli Lilly and Company (NYSE:LLY) on Wednesday, April 25 with “Market Perform” rating. The stock has “Buy” rating by Goldman Sachs on Tuesday, September 27. The stock has “Outperform” rating by Credit Suisse on Friday, October 9. The stock of Eli Lilly and Company (NYSE:LLY) has “Overweight” rating given on Wednesday, July 25 by Cantor Fitzgerald. As per Thursday, July 13, the company rating was maintained by Jefferies. As per Wednesday, July 25, the company rating was downgraded by Berenberg. The firm has “Market Perform” rating given on Monday, October 23 by Leerink Swann. Argus Research maintained Eli Lilly and Company (NYSE:LLY) on Tuesday, August 2 with “Buy” rating. Societe Generale initiated Eli Lilly and Company (NYSE:LLY) on Wednesday, April 6 with “Hold” rating. The firm earned “Buy” rating on Monday, June 5 by Jefferies.

Since July 24, 2018, it had 1 buying transaction, and 27 selling transactions for $354.11 million activity. 7,000 shares were sold by Zulueta Alfonso G, worth $802,480. $2.82M worth of stock was sold by O’Neill Myles on Monday, December 10. On Thursday, July 26 the insider TAI JACKSON P bought $206,437. $63,342 worth of Eli Lilly and Company (NYSE:LLY) shares were sold by Zakrowski Donald A.

Keystone Financial Planning Inc, which manages about $143.92 million and $195.76 million US Long portfolio, upped its stake in Cvs Health (NYSE:CVS) by 9,049 shares to 68,087 shares, valued at $5.36M in 2018Q3, according to the filing. It also increased its holding in Cisco Systems (NASDAQ:CSCO) by 6,874 shares in the quarter, for a total of 196,012 shares, and has risen its stake in Unilever Plc (NYSE:UL).

Analysts await The Clorox Company (NYSE:CLX) to report earnings on February, 4 before the open. They expect $1.32 earnings per share, up 7.32% or $0.09 from last year’s $1.23 per share. CLX’s profit will be $168.50M for 29.24 P/E if the $1.32 EPS becomes a reality. After $1.62 actual earnings per share reported by The Clorox Company for the previous quarter, Wall Street now forecasts -18.52% negative EPS growth.

Investors sentiment decreased to 0.86 in Q3 2018. Its down 0.14, from 1 in 2018Q2. It fall, as 39 investors sold CLX shares while 270 reduced holdings. 84 funds opened positions while 181 raised stakes. 95.79 million shares or 1.06% less from 96.82 million shares in 2018Q2 were reported. Fulton Savings Bank Na has 1,600 shares for 0.02% of their portfolio. Metropolitan Life has 24,383 shares for 0.07% of their portfolio. Dumont And Blake Invest Advsrs Ltd Liability accumulated 0.12% or 2,084 shares. Allsquare Wealth Limited Liability Com has invested 0.01% in The Clorox Company (NYSE:CLX). Federated Invsts Pa accumulated 1,838 shares. 2,675 were accumulated by First Bancorp. Apg Asset Mgmt Nv owns 1.03 million shares. Sonata Group Incorporated invested 0.29% in The Clorox Company (NYSE:CLX). British Columbia Investment Mngmt reported 39,839 shares or 0.06% of all its holdings. Gemmer Asset Mngmt invested in 96 shares. Savings Bank Of Ny Mellon holds 1.66M shares. Apriem Advisors holds 0.78% in The Clorox Company (NYSE:CLX) or 23,738 shares. California-based Elm Advsr Lc has invested 0.01% in The Clorox Company (NYSE:CLX). First has invested 0.11% in The Clorox Company (NYSE:CLX). Meiji Yasuda Asset Ltd has 0.13% invested in The Clorox Company (NYSE:CLX) for 10,343 shares.

More notable recent The Clorox Company (NYSE:CLX) news were published by: Bizjournals.com which released: “Clorox’s Burt’s Bees cuts deal with P&G to build buzz over toothpaste – San Francisco Business Times” on December 31, 2018, also Prnewswire.com with their article: “Catnip Dreams Meet Instagram Inspiration At The Cats On Glass Gallery In Los Angeles – PRNewswire” published on January 09, 2019, Seekingalpha.com published: “The Clorox Company: 1 Top Dividend Stock For 2019… And Beyond – Seeking Alpha” on January 15, 2019. More interesting news about The Clorox Company (NYSE:CLX) were released by: Fool.com and their article: “Better Buy: Clorox vs. Colgate-Palmolive – The Motley Fool” published on January 13, 2019 as well as Seekingalpha.com‘s news article titled: “Clorox shuffles leaders as COO resigns post – Seeking Alpha” with publication date: December 10, 2018.

Among 18 analysts covering The Clorox Company (NYSE:CLX), 3 have Buy rating, 4 Sell and 11 Hold. Therefore 17% are positive. The Clorox Company had 71 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Hold” rating by RBC Capital Markets on Tuesday, August 1. Bank of America maintained the stock with “Neutral” rating in Monday, July 16 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, November 3. The firm has “Underweight” rating by Barclays Capital given on Monday, March 21. On Friday, May 4 the stock rating was maintained by Citigroup with “Neutral”. On Tuesday, June 14 the stock rating was initiated by Atlantic Securities with “Neutral”. On Thursday, November 2 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, October 3. Goldman Sachs downgraded The Clorox Company (NYSE:CLX) rating on Wednesday, July 18. Goldman Sachs has “Sell” rating and $112 target. The company was initiated on Tuesday, July 21 by Sterne Agee CRT.

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.